Duration of response (DoR) and disease control rate (DCR)
Duration of response measures how long a tumour that shrank stays shrunk before growing again; disease control rate adds patients whose cancer stayed stable to those who responded. Together with response rate they describe a drug's activity in trials without a comparison group.
Median DoR is required alongside objective response rate for accelerated approvals because a high response rate that lasts two months is worth little; durable responses (ongoing at 12 months or more) are the hallmark of immunotherapy and of oncogene-targeted drugs in addicted tumours. Disease control rate (CR + PR + stable disease) is a weaker measure because stable disease may reflect slow natural history rather than drug effect, and clinical benefit rate (usually stable disease ≥6 months) is used in endocrine therapy trials of breast cancer where stability is meaningful. Time to response matters clinically for symptomatic patients and is fast for chemotherapy and kinase inhibitors, slower for immunotherapy.
Pages like this
not linked directly; found by shared links- TermDuration of response
Shares Objective response rate (ORR), Accelerated approval, Progression-free survival (PFS).
- IdeaRequire a randomised phase 2 before any phase 3
Shares Objective response rate (ORR), Progression-free survival (PFS).
- TermExternal and synthetic control arms
Shares Single-arm trial, Accelerated approval.
- IdeaProvisional prices for surrogate-endpoint approvals, reset when survival data arrive
Shares Accelerated approval, Progression-free survival (PFS).
- TermProgressive disease and radiographic progression
Shares Complete response (CR) and partial response (PR), Progression-free survival (PFS).
- TermSurrogate endpoint
Shares Objective response rate (ORR), Accelerated approval, Progression-free survival (PFS).
- IdeaAn independent programme that validates surrogate endpoints, setting by setting
Shares Objective response rate (ORR), Accelerated approval, Progression-free survival (PFS).
- Key paperSunRISe-1: TAR-200, a gemcitabine-releasing device placed in the bladder, for BCG-unresponsive non-muscle-invasive bladder cancer